Antibody neutralizing human respiratory syncytial virus

Patent metadata

Field	Value
Publication number	US-10323079-B2
Application number	US-201815928503-A
Country	US
Kind code	B2
Filing date	Mar 22, 2018
Priority date	Oct 29, 2015
Publication date	Jun 18, 2019
Grant date	Jun 18, 2019

Abstract

The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

First claim

The invention claimed is:

1. A method of producing an antibody or antigen binding fragment comprising:
(a) culturing a host cell comprising a polynucleotide encoding an antibody heavy chain variable region and a polynucleotide encoding an antibody light chain variable region under conditions favorable to expression of the polynucleotide; and
(b)recovering the antibody or antigen binding fragment from the host cell and/or culture medium;
wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:7 and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO:8.

2. The method of claim 1 , wherein the host cell comprises an expression vector having the polynucleotide encoding the antibody heavy chain variable region and an expression vector having the polynucleotide encoding the antibody light chain variable region.

3. The method of claim 1 , wherein the host cell comprises an expression vector having both the polynucleotide encoding the antibody heavy chain variable region and the polynucleotide encoding the antibody light chain variable region.

4. The method of claim 1 , wherein the host cell is a Pichia cell or a Chinese hamster ovary cell.

5. The method of claim 1 , wherein the polynucleotide encoding the antibody heavy chain variable region encodes an antibody heavy chain comprising the amino acid sequence of SEQ ID NO:23 and the polynucleotide encoding the antibody light chain encodes an antibody light chain comprising the amino acid sequence of SEQ ID NO:25.

6. The method of claim 5 , wherein the polynucleotide encoding the antibody heavy chain comprises the nucleotide sequence set forth in SEQ ID NO:24 and the polynucleotide encoding the antibody light chain comprises the nucleotide sequence set forth in SEQ ID NO:26.

7. The method of claim 1 , wherein the polynucleotide encoding the antibody heavy chain variable region comprises the nucleotide sequence of SEQ ID NO:17 and the polynucleotide encoding the antibody light chain variable region comprises the nucleotide sequence of SEQ ID NO:18.

Assignees

• Merck Sharp & Dohme

Inventors

• Vora Kalpit A
• Cox Kara S
• Tang Aimin
• Chen Zhifeng
• Distefano Daniel
• Zhang Lan
• Su Hua-Poo

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P31/22

  for herpes viruses · CPC title

• A61P31/20

  for DNA viruses · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title